Business Standard

Risk-reward favourable for Lupin as domestic biz provides cushion to growth

Analysts are now upgrading the stock as they expect a recovery for Lupin moving forward, besides a significant improvement in the company's free cash flows



Ujjval Jauhari
Shares of Lupin have rebounded more than 10 per cent from their 52-week lows seen last week. Though challenges continue for the company, given the regulatory issues raised by the US Food and Drug Administration for its plants, and the drug pricing lawsuit against a host of Indian (including Lupin) and global pharma companies in the US continuing to be an overhang, analysts believe the risk-reward equation is turning favourable for Lupin.

For one, big product launches are expected to start this financial year. The Street is also keeping an eye out for the ramp-up of Solosec. These initiatives can

Don't miss the most important news and views of the day. Get them on our Telegram channel

First Published: Jun 26 2019 | 6:29 PM IST

Explore News

To read the full story, subscribe to BS Premium now, at just Rs 249/ month.

Key stories on are available only to BS Premium subscribers.

Register to